← SynDRA
QUIFLAPON
SynDRA canonical compound SYN0000965 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | ALOX5AP |
|---|
| Mechanism of action | Leukotriene inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- Leukotriene inhibitor
- leukotriene synthesis inhibitor
- ALOX5 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP2C9
- CYP2D6
- CYP3A4
- CYP1A2
- CYP2C19
- HDAC6
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- CP2C9
- GAMT
- GNMT
- GPX4
- HNMT
- KSYK
- NNMT
- PNMT
- SYK
Drug classes
- 5-Lipoxygenase-Activating Protein Inhibitors
Cross-references
Synonyms
- L-686708
- MK 0591
- MK-591
- L-686,708
- quiflaponum
- MK591 compound
- RefChem:178139
- DTXCID4082373
- Quiflapon [INN]
- Quiflapon free acid
- L 686708
- C34H35ClN2O3S
- UNII-9295C885I4
- MFCD00900782
- MK591 free acid
- 2q7m
- MK-0591Quiflapon ?
- SCHEMBL502947
- orb1308037
- SCHEMBL29370879
- SCHEMBL29372303
- SCHEMBL30505315
- NZOONKHCNQFYCI-UHFFFAOYSA-N
- GLXC-02801
- HMS3747O19
- EX-A5139
- LFA66842
- BDBM50029559
- AKOS027420455
- CS-0953
- SB19076
- NCGC00379068-01
- NCGC00379068-02
- NCGC00379068-04
- AC-36773
- HY-10037
- MS-30490
- DB-063158
Look up QUIFLAPON in the interactive SynDRA portal →